ArticleArchives of medical science : AMS2015
Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia.
Article in Archives of medical science : AMS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia.The Cochrane database of systematic reviews · 2022Pooled it
- Pooled it
- Autologous stem cell therapy for peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials.Stem cell research & therapy · 2019Pooled it
- Growth factors for angiogenesis in peripheral arterial disease.The Cochrane database of systematic reviews · 2017Pooled it
- Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease.Stem cells translational medicine · 2021Trial
- Modalities to Deliver Cell Therapy for Treatment of Chronic Limb Threatening Ischemia.Advances in wound care · 2024Review
- Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus.Frontiers in molecular biosciences · 2022Review
- Peripheral arterial disease: Scoping review of patient-centred outcomes.International wound journal · 2019Article
- Hearing regeneration and regenerative medicine: present and future approaches.Archives of medical science : AMS · 2019Article
- Cell therapy for peripheral artery disease.Current opinion in pharmacology · 2018Review
- Skin perfusion pressure for the prediction of wound healing in critical limb ischemia: a meta-analysis.Archives of medical science : AMS · 2018Review
- Autologous Stem Cell Therapy in Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials.Stem cells international · 2018Review
- Functions of the AP-2α gene in activating apoptosis and inhibiting proliferation of gastric cancer cells bothArchives of medical science : AMS · 2017Article
- Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation.Archives of medical science : AMS · 2016Article
- Stem cell therapy in critical limb ischemia: Current scenario and future trends.The Indian journal of radiology & imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOur study was designed to investigate the safety and efficacy of combined autologous bone marrow mononuclear cell (MNC) and gene therapy in comparison to conventional drug therapy in patients with critical limb ischemia (CLI). MATERIAL AND
methodsThirty-two patients with CLI persisting for 12-48 months (average time 27.5 months) were randomized into 2 groups, each group consisting of 16 patients. In the first group, administration of autologous bone marrow MNC and vascular endothelial growth factor (VEGF) plasmid was performed. The patients from the second group were treated pharmacologically with pentoxifylline. Ankle-brachial index (ABI) was measured and angiography was performed before and finally 3 months after treatment. The pain was evaluated using the Visual Analog Scale (VAS) before and after 3 months.
resultsAnkle-brachial index improved significantly from 0.29 ±0.21 to 0.52 ±0.23 (p < 0.001) in 12 patients (75.0%) 3 months after the experimental therapy in group 1. In this group angiography showed the development of collateral vessels. Ischemic ulcers healed completely in 11 patients (68.75%). In group 2 the ABI did not improve in any patient; moreover the complete healing of skin ulcers was not found in any of the patients of this group. Amputation was performed in 4 (25.0%) patients in group 1, and in 8 patients (50%) from group 2.
conclusionsThese data after 3-month follow-up indicate that intramuscular injection of MNC combined with gene therapy in patients with chronic CLI is safe, and a more feasible and effective method of treatment than the conventional therapy. However, both therapies are limited by the degree of microcirculation damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.